For example, the PARP1 gene has been shown to be essential in tumors where BRCA1 or BRCA2 are lowly expressed, thus making PARP inhibitors a candidate for treating subtypes of breast and ovarian cancers [4–7]. This evidence concerns the gene PARP1 and ovarian carcinoma.